Gilead Sciences, Inc.GILDNASDAQ
Loading
EBITDA Over TimeExpanding
Percentile Rank64
3Y CAGR+6.9%
5Y CAGR+21.2%
Year-over-Year Change
Earnings before interest, taxes, depreciation, and amortization
3Y CAGR
+6.9%/yr
vs -3.7%/yr prior
5Y CAGR
+21.2%/yr
Recent deceleration
Acceleration
+10.6pp
Accelerating
Percentile
P64
Within normal range
vs 5Y Ago
2.6x
Strong expansion
Streak
1 yr
Consecutive growthExpanding
| Period | Value | YoY Change |
|---|---|---|
| 2025 | $10.82B | +144.0% |
| 2024 | $4.43B | -57.8% |
| 2023 | $10.50B | +18.6% |
| 2022 | $8.85B | -21.9% |
| 2021 | $11.33B | +174.1% |
| 2020 | $4.13B | -45.3% |
| 2019 | $7.56B | -26.6% |
| 2018 | $10.30B | -35.3% |
| 2017 | $15.93B | -17.1% |
| 2016 | $19.22B | - |